Articles Written by:    SHIRLEY S. WANG     

« Previous  |  Next »

Antipsychotics Raise Death Risk for Alzheimer’s Patients

A study showing that potent antipsychotic drugs raise the risk of death in Alzheimer’s disease heightens worries about their use in managing dementia. The findings, based on a look at 165 patients, aren’t a bolt out of the blue. There have long been ...

From SHIRLEY S. WANG, Wall Street Journal,  9 Jan 2009

J&J’s Poon to Head Ohio State Business School

WSJ’s blog on health and the business of health. “Chriss vast, global experience, demonstrated business acumen, and a deep commitment to innovation and scientific research and development will be invaluable assets for our faculty, students, staff ...

From SHIRLEY S. WANG, Wall Street Journal,  9 Jan 2009
Related Topics: Wall Street Journal

Psychiatrists Bash Back at Critics of Diagnostic Manual Revision

The American Psychiatric Association is striking back at critics over complaints about secrecy in the work on a new version of the Diagnostic and Statistical Manual of Mental Disorders. Known as the DSM, the tome is the definitive resource for the ...

From SHIRLEY S. WANG, Wall Street Journal,  8 Jan 2009

Alzheimer’s Groups Disagree on Screening for Memory Problems

Is widespread screening of the elderly for Alzheimer’s disease and other problems of memory a good idea? Why screen? People with memory problems can be referred for a complete evaluation and identified earlier in the disease process, perhaps prompting ...

From SHIRLEY S. WANG, Wall Street Journal,  10 Dec 2008
Related Topics: Richard Powers

FDA Blow to Basilea Leads to Deal Talk

WSJ’s blog on health and the business of health. “This might be an interesting entry point for a new investor, possibly Basilea’s partner for ceftobiprole, Johnson & Johnson,” Birgit Kulhoff, an analyst at private bank Rahn & Bodmer in Zurich, told ...

From SHIRLEY S. WANG, Wall Street Journal,  26 Nov 2008
Related Topics: Food and Drug Administration,  Johnson & Johnson,  Dow Jones,  Citigroup,  Wall Street Journal

Scientists Pinpoint Research Priorities for 14 Drugs Used ‘Off-Label’

Psychiatric meds and the widely prescribed blood thinner Coumadin are among the drugs most frequently prescribed outside their FDA-approved instructions and for which there are safety concerns, say researchers at Stanford. The findings, published in ...

From SHIRLEY S. WANG, Wall Street Journal,  24 Nov 2008
Related Topics: Stanford University,  Food and Drug Administration,  Joshua Cohen

Wyeth Names Kamarck to Run Factories

WSJ’s blog on health and the business of health. When Wyeth named Michael Kamarck as its new head of manufacturing this week, we asked, “Who is that guy?” Wyeth indulged us. And we found out Kamarck, 57, was trained as a biochemist, and that he’s ...

From SHIRLEY S. WANG, Wall Street Journal,  21 Nov 2008
Related Topics: Bayer,  Wall Street Journal

J&J Gets Caught in a Sling Over Internet Motrin Ad

Johnson & Johnson, the maker of Baby Powder and Band-aids, has masterfully linked its corporate image to babies for decades. So it is especially interesting that a misstep in the baby space sparked an uproar in the Internet’s social networking space ...

From SHIRLEY S. WANG, Wall Street Journal,  17 Nov 2008
Related Topics: Johnson & Johnson,  Twitter Inc,  Facebook Inc.

FDA Delays Take Toll on Neuroscience Drug Development

The FDA has even the neuroscience crowd scratching their heads. Some folks from the Neurotechnology Industry Organization, a trade group for neuroscience companies, and three of its members stopped by Health Blog HQ today. Our chat really heated up ...

From SHIRLEY S. WANG, Wall Street Journal,  10 Nov 2008
Related Topics: Food and Drug Administration

Wyeth Joins R&D Restructuring Parade

Wyeth is overhauling its early-stage research by slashing in half the number of therapeutic areas and diseases for which it will pursue new medicines. The idea is to concentrate on more innovative products and get them to market faster. Wyeth’s ...

From SHIRLEY S. WANG, Wall Street Journal,  28 Oct 2008
Related Topics: Bristol-Myers Squibb,  Pfizer Inc.

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry

Enter a url from sourcewatch.org or wikipedia.org:


recommend removal

close